Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.37

+0.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (26899)	5/26/2008 4:15:39 AM
From: Biomaven	Read Replies (2) of 52153

But at the end of the day I believe a lot more late-stage drugs have died or been delayed by QTc issues than by animal tox studies. The only example I can recall off-hand of the 2-year animal studies actually being a gating factor is for Isotechnika's drug, and that was because they changed to an isomer after they had already started their clinical program. I can't recall if those studies are completed or not, but I remember thinking they might be a problem because the comparator cyclosporine is actually somewhat carcinogenic in animal studies. And while you guys are slaving away over hot keyboards (or whatever), here is where I am: flickr.com The elevation in that photo was come by honestly - the shot was taken about half way up a hike to the base of a waterfall and I'm still kind of sore today :) Having fantastic weather and it's light until nearly midnight - can't imagine what it's like in mid-winter though. Folks living in these valleys might never see the sun for long portions of winter - the mountains on either side seem high enough to prevent the low sun from ever being visible. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next